全球肌肉萎缩症市场规模、份额、趋势和成长分析报告（2026-2034年）

预计肌肉萎缩症 (AMD) 市场将从 2025 年的 269.1 亿美元增长到 2034 年的 996.8 亿美元，2026 年至 2034 年的复合年增长率为 15.66%。

由于肌肉萎缩症和恶病质等疾病的盛行率不断上升，全球肌肉萎缩症市场正稳定成长。人口老化和慢性病的发病率上升也促使人们对有效治疗方法的需求增加。生物技术和基因治疗研究的进步正在推动创新治疗方法的开发。公众意识的提高和诊断能力的增强进一步推动了市场扩张。

关键成长要素包括对罕见疾病研究投入的增加和监管激励措施的支持。製药公司正专注于标靶治疗和个人化医疗方法。临床试验的扩展以及研究机构与生物技术公司之间的合作正在加速创新。此外，新兴国家医疗基础设施的改善也有助于提高患者获得治疗的机会。

展望未来，基因编辑技术和再生医学的进步预计将对市场产生积极影响。早期诊断和支持性护理计画的扩展有望改善患者的治疗效果。罕见疾病研究经费的增加将开闢新的成长途径。在科学不断突破的背景下，全球肌肉萎缩症（AMD）市场预计将持续成长。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章 全球肌肉萎缩症市场：依类型划分

• 市场分析、洞察与预测
• 肌肉萎缩症
• 肌肉萎缩

第五章 全球肌肉萎缩症市场：依治疗类型划分

• 市场分析、洞察与预测
• 製药
• 物理治疗
• 营养疗法
• 外科手术
• 基因治疗
• 其他的

第六章 全球肌肉萎缩症市场：依最终用户划分

• 市场分析、洞察与预测
• 医院
• 復健设施
• 专科诊所
• 其他的

第七章 全球肌肉萎缩症市场：依地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第八章 竞争情势

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第九章：公司简介

• 主要公司的市占率分析
• 公司简介
  • Biogen
  • F. Hoffmann-La Roche
  • Novartis
  • Ionis Pharmaceuticals
  • Sarepta Therapeutics
  • Nippon Shinyaku
  • PTC Therapeutics
  • Teva Pharmaceutical Industries
  • Regeneron Pharmaceuticals
  • Acceleron Pharma Inc

The Muscle Wasting Disorders Market size is expected to reach USD 99.68 Billion in 2034 from USD 26.91 Billion (2025) growing at a CAGR of 15.66% during 2026-2034.

The Global Muscle Wasting Disorders Market is growing steadily due to increasing prevalence of conditions such as muscular dystrophy and cachexia. Rising aging populations and higher incidence of chronic diseases are contributing to demand for effective treatment options. Advances in biotechnology and gene therapy research are supporting the development of innovative therapies. Growing awareness and improved diagnostic capabilities are further driving market expansion.

Key growth drivers include increased investment in rare disease research and supportive regulatory incentives. Pharmaceutical companies are focusing on targeted therapies and personalized medicine approaches. Expanding clinical trials and collaboration between research institutions and biotech firms are accelerating innovation. Additionally, improved healthcare infrastructure in emerging economies is enhancing access to treatment.

Looking ahead, the market is expected to benefit from advancements in gene editing and regenerative medicine. Early diagnosis and supportive care programs will improve patient outcomes. Increased funding for rare disease research will create new growth avenues. As scientific breakthroughs continue, the Global Muscle Wasting Disorders Market is projected to witness sustained development.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Type

• Muscular Dystrophy
• Muscular Atrophy

By Treatment Type

• Medications
• Physical Therapy
• Nutritional Therapy
• Surgery
• Gene Therapy
• Others

By End-user

• Hospitals
• Rehab Centers
• Specialty Clinics
• Others

COMPANIES PROFILED

• Biogen, F HoffmannLa Roche, Novartis, Ionis Pharmaceuticals, Sarepta Therapeutics, Nippon Shinyaku, PTC Therapeutics, Teva Pharmaceutical Industries, Regeneron Pharmaceuticals, Acceleron Pharma Inc
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL MUSCLE WASTING DISORDERS MARKET: BY TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Type
• 4.2. Muscular Dystrophy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Muscular Atrophy Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL MUSCLE WASTING DISORDERS MARKET: BY TREATMENT TYPE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Treatment Type
• 5.2. Medications Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Physical Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Nutritional Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Surgery Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Gene Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL MUSCLE WASTING DISORDERS MARKET: BY END-USER 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End-user
• 6.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Rehab Centers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Specialty Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL MUSCLE WASTING DISORDERS MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Type
  • 7.2.2 By Treatment Type
  • 7.2.3 By End-user
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Type
  • 7.3.2 By Treatment Type
  • 7.3.3 By End-user
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Type
  • 7.4.2 By Treatment Type
  • 7.4.3 By End-user
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Type
  • 7.5.2 By Treatment Type
  • 7.5.3 By End-user
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Type
  • 7.6.2 By Treatment Type
  • 7.6.3 By End-user
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL MUSCLE WASTING DISORDERS INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Biogen
  • 9.2.2 F. Hoffmann-La Roche
  • 9.2.3 Novartis
  • 9.2.4 Ionis Pharmaceuticals
  • 9.2.5 Sarepta Therapeutics
  • 9.2.6 Nippon Shinyaku
  • 9.2.7 PTC Therapeutics
  • 9.2.8 Teva Pharmaceutical Industries
  • 9.2.9 Regeneron Pharmaceuticals
  • 9.2.10 Acceleron Pharma Inc